Natera, Inc. $NTRA Position Lifted by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its position in Natera, Inc. (NASDAQ:NTRA) by 7.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,565 shares of the medical research company’s stock after purchasing an additional 4,190 shares during the period. Illinois Municipal Retirement Fund’s holdings in Natera were worth $25,445,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of NTRA. Trust Co. of Vermont acquired a new position in shares of Natera in the 2nd quarter valued at $26,000. Elevation Wealth Partners LLC bought a new stake in shares of Natera in the 2nd quarter valued at $30,000. Continuum Advisory LLC bought a new stake in shares of Natera in the 2nd quarter valued at $33,000. Rakuten Securities Inc. acquired a new stake in Natera during the 2nd quarter worth $35,000. Finally, Burkett Financial Services LLC acquired a new stake in Natera during the 3rd quarter worth $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Down 2.6%

NTRA opened at $311.98 on Wednesday. The stock has a market capitalization of $45.24 billion, a P/E ratio of -273.67 and a beta of 1.55. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The firm’s fifty day simple moving average is $379.93 and its 200 day simple moving average is $270.42.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. Natera’s revenue for the quarter was up 34.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.64) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.20 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider John Fesko sold 302 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $400.01, for a total transaction of $120,803.02. Following the completion of the transaction, the insider directly owned 195,276 shares in the company, valued at approximately $78,112,352.76. This trade represents a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares in the company, valued at approximately $36,004,085.80. This represents a 4.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 47,056 shares of company stock valued at $17,760,989. 5.05% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. TD Cowen lifted their target price on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Stephens increased their price target on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Rothschild & Co Redburn initiated coverage on Natera in a report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective on the stock. Finally, Royal Bank Of Canada lifted their price objective on Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% to about $794 million, beating estimates, and Natera raised its 2026 sales outlook as test volumes—particularly oncology testing—accelerated. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Positive Sentiment: Management highlighted a long-term goal of $6 billion in revenue by 2029, supported by Signatera growth, broader reimbursement and continued investment. Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
• Positive Sentiment: Natera is collaborating with Incyte on a Phase 2 colorectal cancer trial, which could support its oncology testing business, though the commercial impact will depend on trial results and adoption. Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
• Neutral Sentiment: A report listed short interest at zero shares as of November 10, a figure that does not indicate meaningful short positioning; the report’s description of a significant increase appears inconsistent with that number.
• Negative Sentiment: Despite the revenue beat, Natera’s quarterly loss of $0.42 per share was wider than the $0.28 loss analysts expected, highlighting ongoing profitability concerns. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Negative Sentiment: Analysts cut price targets, including Robert W. Baird’s reduction to $403 from $458, while maintaining an Outperform rating. JPMorgan also reportedly lowered its target, adding a cautious note despite the improved outlook. Robert W. Baird Stock Recommendations Natera Stock Gets Price Target Cut from JPMorgan Chase & Co.

Natera Company Profile

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.